| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA1806528
Max Phase: Preclinical
Molecular Formula: C74H103N19O23S
Molecular Weight: 1658.82
Molecule Type: Protein
Associated Items:
Representations
Canonical SMILES: CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@@H](CCC(N)=O)NC(=O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
Standard InChI: InChI=1S/C74H103N19O23S/c1-42(81-69(111)50(17-20-58(76)96)84-71(113)51(18-21-59(77)97)85-70(112)49(16-19-57(75)95)82-61(99)38-90-23-25-91(39-63(102)103)27-29-93(41-65(106)107)30-28-92(26-24-90)40-64(104)105)67(109)88-54(33-44-12-14-46(94)15-13-44)68(110)80-37-60(98)83-55(34-45-36-79-48-11-7-6-10-47(45)48)73(115)86-52(22-31-117-2)72(114)89-56(35-62(100)101)74(116)87-53(66(78)108)32-43-8-4-3-5-9-43/h3-15,36,42,49-56,79,94H,16-35,37-41H2,1-2H3,(H2,75,95)(H2,76,96)(H2,77,97)(H2,78,108)(H,80,110)(H,81,111)(H,82,99)(H,83,98)(H,84,113)(H,85,112)(H,86,115)(H,87,116)(H,88,109)(H,89,114)(H,100,101)(H,102,103)(H,104,105)(H,106,107)/t42-,49+,50+,51+,52-,53-,54-,55-,56-/m0/s1
Standard InChI Key: REDJMWJKGVPBKU-OUMHZCMBSA-N
Associated Targets(Human)
Cholecystokinin B receptor 3550 Activities
Cholecystokinin A receptor 4460 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Associated Targets(non-human)
Cholecystokinin B receptor 729 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 1658.82 | Molecular Weight (Monoisotopic): 1657.7195 | AlogP: | #Rotatable Bonds: |
| Polar Surface Area: | Molecular Species: | HBA: | HBD: |
| #RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
| CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
| Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
References
| 1. Kolenc-Peitl P, Mansi R, Tamma M, Gmeiner-Stopar T, Sollner-Dolenc M, Waser B, Baum RP, Reubi JC, Maecke HR.. (2011) Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor., 54 (8): [PMID:21456601] [10.1021/jm101279a] |
Source
Source(1):